R3HDM2: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: R3HDM2

NCBI ID: G22864

R3HDM2

R3HDM2: A Potential Drug Target and Biomarker for Neurological Disorders

R3HDM2 (CAG6) is a protein that is expressed in the brain and is known for its role in the regulation of neural stem cells. It is a potential drug target (or biomarker) for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases.

The R3HDM2 protein is composed of 1,122 amino acids and has a molecular weight of 17.9 kDa. It is located in the brain and is expressed in the lines of the cerebral cortical regions. R3HDM2 is a key regulator of neural stem cells and has been shown to play a role in the development and maintenance of neural stem cells.

One of the key functions of R3HDM2 is its ability to promote the self-renewal of neural stem cells. Self-renewal is the process by which stem cells maintain their number and are able to replace themselves with new stem cells. This is important for the development and maintenance of neural stem cells, which are important for the repair and regeneration of damaged neural tissue.

Another function of R3HDM2 is its role in the regulation of cell survival. R3HDM2 has been shown to play a role in the regulation of cell survival by promoting the production of factors that promote cell survival, such as the protein p53. This is important because damaged Neural tissue is often replaced with damaged cells that do not survive and are not able to repair themselves.

In addition to its role in cell survival and self-renewal, R3HDM2 has also been shown to play a role in the regulation of neural stem cell proliferation. R3HDM2 has been shown to promote the production of factors that promote neural stem cell proliferation, such as the protein Brn3. This is important because neural stem cells are important for the development and maintenance of neural tissue, and the regulation of their proliferation is important for the development of neural tissue repair and regeneration.

The potential drug targets for R3HDM2 are numerous and range from neurodegenerative diseases to cancer. For example, R3HDM2 has been shown to be a potential drug target for Alzheimer's disease, with studies showing that R3HDM2 levels are decreased in the brains of individuals with Alzheimer's disease and that R3HDM2 inhibitors have been shown to be effective in animal models of Alzheimer's disease.

In addition to its potential drug targets, R3HDM2 is also a potential biomarker for various neurological disorders. For example, R3HDM2 has been shown to be decreased in the brains of individuals with Parkinson's disease and has been shown to be a potential biomarker for Parkinson's disease. Additionally, R3HDM2 has been shown to be decreased in the brains of individuals with Alzheimer's disease, which could make it a potential biomarker for Alzheimer's disease.

Overall, R3HDM2 is a protein that has the potential to be a drug target or biomarker for a variety of neurological disorders. Further research is needed to fully understand its functions and to develop effective treatments for the various disorders that it is involved in.

Protein Name: R3H Domain Containing 2

The "R3HDM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about R3HDM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets